Voyager Therapeutics' anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD.
Cirrus Aircraft delivered 13.1% revenue growth in 2025 to $1.35B, with margin expansion, despite new product launch pressures ...
Everybody wants to look their best on prom night, right? The Elmira Economic Opportunity Program Inc. is giving teens the ...
Early feedback from Hop Products Australia, Ryefield Hops and Hilltop Hops indicates a strong 2026 harvest, with high quality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results